PDIA4: Potential Drug Target and Biomarker for Alzheimer's, Parkinson's and MS

Target Name: PDIA4

NCBI ID: G9601

PDIA4

PDIA4: Potential Drug Target and Biomarker for Alzheimer's, Parkinson's and MS

PDIA4 (PDIA4 variant 2) is a protein that is expressed in the brain and is known for its role in the development and progression of various neurological disorders, including Alzheimer's disease. The protein is a key component of the presenilin system, which is a network of proteins that helps maintain the integrity of brain cells.

Research has shown that PDIA4 is involved in the formation of beta-amyloid plaques, which are thought to be a hallmark of Alzheimer's disease. The beta-amyloid plaques are composed of aggregated amyloid particles that can interact with and damage brain cells, leading to the symptoms of Alzheimer's disease.

In addition to its role in the formation of beta-amyloid plaques, PDIA4 has also been shown to be involved in the regulation of neurotransmitter release and the modulation of pain perception.

As a potential drug target, PDIA4 is an attractive target for researchers because of its involvement in the development and progression of Alzheimer's disease. By blocking the activity of PDIA4, researchers hope to reduce the formation of beta-amyloid plaques and slow the progression of the disease.

In addition to its potential as a drug target, PDIA4 is also a potential biomarker for the early detection of Alzheimer's disease. The protein is expressed in the brain and can be easily measured using techniques such as Western blotting. By detecting the level of PDIA4 in brain tissue or fluids, researchers may be able to diagnose Alzheimer's disease at an early stage when the protein is still present.

PDIA4 is also a potential target for other neurological disorders, including Parkinson's disease and multiple sclerosis. These disorders are characterized by the progressive loss of brain cells and the development of characteristic symptoms.

In conclusion, PDIA4 is a protein that is expressed in the brain and is involved in the formation of beta-amyloid plaques, which are a hallmark of Alzheimer's disease. As a potential drug target and biomarker, PDIA4 is an attractive target for researchers because of its involvement in the development and progression of these disorders. Further research is needed to fully understand the role of PDIA4 in these diseases and to develop effective treatments.

Protein Name: Protein Disulfide Isomerase Family A Member 4

The "PDIA4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PDIA4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets